Epigenetics in the Hematologic Malignancies|
The authors provide an overview of the major protagonists in epigenetic regulation, their aberrant role in myeloid malignancies, prognostic significance and potential for therapeutic targeting. [Haematologica] Full Article
Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.
ARIAD Announces Longer-Term Safety and Efficacy Data of Ponatinib from PACE and Phase I Clinical Trials|
ARIAD Pharmaceuticals, Inc. announced longer-term follow up from its Phase I and pivotal Phase II trials of Iclusig® (ponatinib), its approved BCR-ABL inhibitor, in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. [Press release from ARIAD Pharmaceuticals, Inc. discussing research presented at the 2014 American Society of Clinical Oncology (ASCO), Chicago] Press Release
Stem Cell Transplant without Radiation or Chemotherapy Pre-Treatment Shows Promise
Researchers at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center report promising outcomes from a clinical trial with patients with a rare form of bone marrow failure who received a hematopoietic stem cell transplant after pre-treatment with immunosuppressive drugs only. [Press release from Dana-Farber/Boston Children’s Cancer and Blood Disorders Center discussing research presented at the 56th annual meeting of the American Society of Hematology, San Francisco] Press Release
Fate Therapeutics Unveils Preclinical Findings of Newly-Identified Small Molecule Modulator Combination for Ex Vivo Programming of Mobilized Peripheral Blood
Fate Therapeutics, Inc. released preclinical data highlighting the pharmacological properties of ex vivo programmed hematopoietic cells sourced from mobilized peripheral blood. [Press release from Fate Therapeutics, Inc. discussing research presented at the 56th annual meeting of the American Society of Hematology, San Francisco] Press Release
Kiadis Pharma Presents Positive Data from a Pre-Specified Interim Analysis of the Phase II Clinical Program with Its Lead Product ATIR™
Kiadis Pharma B.V. announced positive interim data from the ongoing Phase II clinical study with its lead product ATIR™. ATIR™ is a cell-based product designed to enable stem cell transplantations from partially matched family donors for blood cancer patients who do not have a standard of care stem cell donor available. [Press release from Kiadis Pharma B.V. discussing research presented at the 56th annual meeting of the American Society of Hematology, San Francisco] Press Release
From our sponsor:
View immunology lectures, protocols and other resources on the Human Immunology Portal.